Savara (NASDAQ:SVRA) Earns "In-Line" Rating from Evercore ISI

Evercore ISI reaffirmed their in-line rating on shares of Savara (NASDAQ:SVRA - Free Report) in a report issued on Wednesday morning, MarketBeat reports. Evercore ISI currently has a $5.00 target price on the stock, down from their previous target price of $7.00.

A number of other equities analysts have also recently issued reports on SVRA. HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of Savara in a report on Tuesday, October 8th. JMP Securities reissued a "market outperform" rating and set a $9.00 target price on shares of Savara in a research note on Tuesday, October 1st. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $10.17.

Savara Trading Down 15.1 %

Shares of NASDAQ:SVRA traded down $0.58 during trading on Wednesday, reaching $3.25. The stock had a trading volume of 3,171,524 shares, compared to its average volume of 1,209,347. Savara has a 52 week low of $3.25 and a 52 week high of $5.70. The firm's fifty day moving average is $3.96 and its 200 day moving average is $4.22. The company has a current ratio of 11.31, a quick ratio of 11.31 and a debt-to-equity ratio of 0.26.

Savara (NASDAQ:SVRA - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.11). On average, equities research analysts forecast that Savara will post -0.44 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Janus Henderson Group PLC lifted its holdings in shares of Savara by 41.1% in the first quarter. Janus Henderson Group PLC now owns 2,563,620 shares of the company's stock valued at $12,754,000 after purchasing an additional 746,407 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Savara by 2.5% in the 1st quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company's stock worth $30,197,000 after buying an additional 148,673 shares during the last quarter. Swiss National Bank bought a new position in shares of Savara in the first quarter valued at approximately $732,000. Frazier Life Sciences Management L.P. grew its holdings in shares of Savara by 103.9% in the second quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company's stock valued at $32,874,000 after acquiring an additional 4,157,385 shares in the last quarter. Finally, Nantahala Capital Management LLC increased its position in shares of Savara by 198.2% during the second quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company's stock valued at $20,879,000 after acquiring an additional 3,443,541 shares during the last quarter. 87.93% of the stock is owned by institutional investors.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.